Compare Omnicom Group Inc. (OMC) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Omnicom Group Inc. vs Pfizer Inc — how do they compare? Omnicom Group Inc. trades at $76.46 (market cap $20.97B), while Pfizer Inc trades at $28.18 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 7.6× Omnicom Group Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Omnicom Group Inc. for 63 Days and Pfizer Inc for 158 Days on average.
| OMC | PFE | |
|---|---|---|
Market Cap | $20.97B | $158.56B |
Volume | 2,092,899 | 44,138,282 |
Sector | Media | Health |
52-Week High | $88.94 | $29.02 |
52-Week Low | $67.27 | $23.67 |
Typical Hold Time | 63 Days | 158 Days |
Enterprise Value | $29.05B | $210.06B |
Dividend Yield | 4.19% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Omnicom Group (OMC) trades at $76.32, up 1.94% on the day, with a bullish technical signal but mixed earnings history. The company reported a net loss of $54.5 million in 2025 despite revenue growth to $17.27 billion, with a high P/E ratio of 206.62 but attractive P/S of 0.86. Recent news highlights leadership in digital marketing and $3.3 billion in new H1 2026 billings, supporting positive sentiment.
Outlook is cautiously optimistic given analyst consensus price target of $100.50 (32% upside) and strong institutional interest, but risks include ad market volatility, high debt, and thin net margins. The stock offers value through a 4.2% dividend yield and post-merger synergies, though investors should monitor earnings consistency and macroeconomic pressures on advertising spend.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
